Ibogaine is not explicitly scheduled or prohibited under Cameroonian national drug law, placing it in an unscheduled legal grey zone — though this does not equate to formal legality or regulatory approval. Last verified: April 22, 2026.

Current Legal Status

Cameroon has not enacted specific legislation scheduling ibogaine or its parent plant, Tabernanthe iboga. The country's primary drug control framework is drawn from the Law No. 97/019 of September 9, 1997 on the Control of Narcotic Drugs and Psychotropic Substances, which adopts schedules largely mirroring the United Nations 1971 Convention on Psychotropic Substances. Ibogaine does not appear on the UN 1971 Convention's schedules, nor is it listed in Cameroon's own controlled substances annexes.

This means that, strictly speaking, possession and use of ibogaine or raw iboga root bark is not a criminal offense under the current statutory text. However, the legal situation carries important caveats:

  • Cameroon has no formal regulatory pathway — such as a clinical trial authorisation or compassionate use permit — for ibogaine as a pharmaceutical substance.
  • Importing finished pharmaceutical ibogaine preparations could implicate medicines importation regulations enforced by the Ministry of Public Health (Ministère de la Santé Publique).
  • Broad prosecutorial discretion exists under Cameroonian law, and enforcement may vary by region and local authority.

Traditional Context: Cameroon is part of the Central African region where Tabernanthe iboga is indigenous. The Bwiti spiritual tradition — which uses iboga sacramentally — is practised by Fang and Beti communities in the southern and central regions of the country. Traditional use has never been criminalised and carries cultural legitimacy recognised informally by the state.

Religious and Traditional Carve-Outs

Unlike Gabon, which has granted iboga the status of a national treasure, Cameroon has no formal legislative carve-out explicitly protecting Bwiti sacramental use. Nevertheless, traditional and religious use of iboga has historically proceeded without state interference. No reported prosecutions related to Bwiti iboga ceremonies in Cameroon have been documented in publicly available court records or legal literature.

Treatment Centers

Cameroon does not have internationally advertised, medically supervised ibogaine treatment clinics comparable to those operating in Mexico, South Africa, or Portugal. Treatment activity, where it exists, falls into two broad categories:

  • Traditional Bwiti healers (ngangas): Initiatory and therapeutic iboga ceremonies are conducted within Bwiti communities in the south and centre of the country, primarily in and around Yaoundé and forested southern regions. These are not biomedical settings.
  • Informal or underground providers: Some practitioners offer ibogaine-assisted sessions outside any recognised clinical framework; quality, safety standards, and practitioner credentials cannot be independently verified.

For a full directory of vetted ibogaine treatment centres near or accessible from Cameroon, visit our clinic directory.

How People Access Ibogaine in Cameroon

The following describes observed patterns of access. This is factual reporting and does not constitute a recommendation.

  • Bwiti ceremony participation: Individuals seeking iboga for addiction interruption, spiritual initiation, or psychological work sometimes seek out traditional Bwiti communities. Formal initiation rites involve multi-day ceremonies under nganga supervision.
  • Raw iboga root bark sourcing: Tabernanthe iboga grows natively in Central and West Africa, including parts of Cameroon. Root bark is available in some local markets and from traditional medicine vendors (tradipraticiens), though quality, potency, and alkaloid content are uncontrolled.
  • Travel abroad: Cameroonians or expatriates seeking structured, medically supervised ibogaine therapy typically travel to clinics in South Africa, Gabon, Portugal, or Mexico, where regulated or semi-regulated options exist.
  • Ibogaine HCl via informal networks: Pharmaceutical-grade ibogaine hydrochloride is not legally available through Cameroonian pharmacies. Some individuals obtain it through unregulated international channels, a practice that carries legal risk depending on origin and transit countries.

Safety Warning: Ibogaine carries significant cardiac risk, including QT prolongation and potentially fatal arrhythmias. Administration outside a medically supervised setting — including traditional ceremonies — carries serious health risks. Medical screening, ECG testing, and qualified monitoring are strongly recommended regardless of legal context.

Recent Legal Developments

No major legislative changes specifically addressing ibogaine or iboga have been enacted or publicly proposed in Cameroon within the past two years. Key observations include:

  • Regional coordination: Cameroon participates in the Economic Community of Central African States (ECCAS) and has observer relationships with the African Union Drug Control Programme. Neither body has issued binding regulations scheduling ibogaine as of 2026.
  • WHO pre-review: The World Health Organization's Expert Committee on Drug Dependence (ECDD) has conducted preliminary reviews of ibogaine in recent years. Should the ECDD recommend UN scheduling, Cameroon — as a signatory to the 1971 Convention — would be obligated to implement corresponding domestic controls. No final UN scheduling recommendation has been adopted as of 2026.
  • Growing research interest: International clinical research on ibogaine for opioid use disorder and PTSD has increased globally, leading some African health ministries to monitor the issue. No formal policy review process in Cameroon has been publicly announced.
  • Traditional medicine policy: Cameroon's National Traditional Medicine Policy, updated within recent years, has moved toward greater integration of traditional healing practices into the health system. This could, in principle, offer a future framework for the regulated practice of iboga-based traditional therapy, though no specific steps have been taken.

Risks of Seeking Treatment in Cameroon

Individuals considering ibogaine or iboga access in Cameroon should be aware of the following risk factors:

  • No quality control: There is no regulatory authority testing iboga root bark or ibogaine preparations sold or used in Cameroon for purity, alkaloid concentration, or contamination. Dosing in traditional settings is empirical rather than pharmacometric.
  • No minimum clinical standards: Medically supervised ibogaine treatment requires pre-treatment cardiac screening (ECG), drug interaction screening, on-site emergency capacity, and post-session monitoring. None of these are mandated or reliably present in informal or traditional Cameroonian settings.
  • Legal ambiguity: While ibogaine is unscheduled, the absence of a clear legal status means that enforcement actions — particularly at borders or involving foreign nationals — cannot be fully predicted. Prosecutorial discretion could expose individuals to charges under broader public health or medicines statutes.
  • Practitioner verification: There is no licensing body for ibogaine practitioners or traditional healers administering iboga in clinical contexts in Cameroon. Due diligence on practitioner background and experience is the individual's sole responsibility.
  • Healthcare infrastructure: Should a medical emergency occur during a session, access to emergency cardiology services in rural or peri-urban areas where ceremonies may take place can be severely limited.
  • Polydrug interactions: Ibogaine has dangerous interactions with opioids, SSRIs, stimulants, and other substances. Without medical screening, individuals with undisclosed substance use or cardiac conditions face elevated mortality risk.

Frequently Asked Questions

Ibogaine is not explicitly listed in Cameroon's controlled substances schedules, making it legally unscheduled rather than formally legal or illegal. Cameroon's drug law (Law No. 97/019 of 1997) mirrors UN 1971 Convention schedules, and ibogaine does not appear on those schedules. However, this unscheduled status does not mean ibogaine is affirmatively authorised as a medicine, and legal risk cannot be entirely excluded — particularly around importation or administration in a medical context without proper authorisation.
There is no formal statutory carve-out protecting Bwiti iboga use in Cameroon as there is in Gabon. However, traditional and religious use of iboga has a long history in southern Cameroon and has not been subject to documented prosecution. The Cameroonian state has generally tolerated traditional healing practices, and Bwiti ceremonies continue to operate in practice. The legal protection is de facto rather than de jure.
Currently, there are no internationally recognised, medically supervised ibogaine treatment clinics operating in Cameroon. Those seeking structured, clinical-standard treatment typically travel to licensed or regulated facilities in countries such as South Africa, Portugal, Mexico, or Gabon. Our clinic directory lists vetted options by country and region.
Yes. If the United Nations Expert Committee on Drug Dependence (ECDD) issues a formal recommendation to schedule ibogaine under the 1971 Convention, Cameroon — as a signatory — would be required to implement those controls domestically. The WHO has conducted preliminary ibogaine reviews, and the question is under active international discussion. Domestically, if Cameroon's Ministry of Public Health initiated a review, it could add ibogaine to national schedules independently of UN action. Neither process has formally advanced as of 2026.
While iboga root bark may be available through traditional medicine vendors in parts of Cameroon, there is no quality control, standardised preparation, or dosing guidance attached to market purchases. Alkaloid content varies enormously between samples, plants, and parts of the root. Purchasing and self-administering iboga without medical screening, cardiac evaluation, and professional supervision poses a serious and potentially fatal risk. This applies regardless of the legal status of the substance.
Medical tourism for ibogaine to Cameroon carries meaningful risks. There are no regulated clinical facilities, no mandatory safety standards for providers, limited emergency medical infrastructure in many areas, and no legal framework that explicitly protects patients or practitioners. Anyone considering this route should conduct extensive due diligence on the specific provider, insist on pre-treatment cardiac and medical screening, and have a clear emergency plan. Compared to established clinical destinations, the risk profile in Cameroon is significantly higher.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.